Search

Your search keyword '"Visconti, Valeria"' showing total 3 results
Start Over Author "Visconti, Valeria" Database OpenAIRE
3 results on '"Visconti, Valeria"'

1. Monoclonal Antibodies in Gynecological Cancer: A Critical Point of View

Author

Bellati, Filippo, Napoletano, Chiara, Gasparri, Maria Luisa, Visconti, Valeria, Zizzari, Ilaria Grazia, Ruscito, Ilary, Caccetta, Jlenia, Rughetti, Aurelia, Benedetti-Panici, Pierluigi, and Nuti, Marianna

Subjects
Article Subject
Abstract

During the last decades, several improvements in treating gynecological malignancies have been achieved. In particular, target therapies, mostly monoclonal antibodies, have emerged as an attractive option for the treatment of these malignancies. In fact, various molecular-targeted agents have been developed for a variety of malignancies with the objective to interfere with a precise tumor associated receptor, essential for cancer cell survival or proliferation, blocking its function, of the cancer cells. Alternatively, monoclonal antibodies have been developed to block immune suppression or enhance functions of immune effector cells. So far, several monoclonal antibodies have been tested for clinical efficacy for the treatment of gynecological cancers. Antibodies against Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) have been used in different neoplasms such as ovarian and cervical cancer. Catumazumab, a bivalent antibody against CD3 and EpCAM, is effective in the treatment of neoplastic ascites. Other antibodies are peculiar for specific cancer-associated antigen such as Oregovomab against CA125 or Farletuzumab against the folate receptor. Here we describe the preclinical and clinical experience gained up to now with monoclonal antibodies in tumors of the female genital tract and trace future therapeutic and research venues.

Published
2011
Full Text
View/download PDF

3. Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy

Author

Maria Pia Sormani, Irene Schiavetti, Matilde Inglese, Luca Carmisciano, Alice Laroni, Caterina Lapucci, Valeria Visconti, Carlo Serrati, Ilaria Gandoglia, Tiziana Tassinari, Germana Perego, Giampaolo Brichetto, Paola Gazzola, Antonio Mannironi, Maria Laura Stromillo, Cinzia Cordioli, Doriana Landi, Marinella Clerico, Elisabetta Signoriello, Eleonora Cocco, Jessica Frau, Maria Teresa Ferrò, Alessia Di Sapio, Livia Pasquali, Monica Ulivelli, Fabiana Marinelli, Matteo Pizzorno, Graziella Callari, Rosa Iodice, Giuseppe Liberatore, Francesca Caleri, Anna Maria Repice, Susanna Cordera, Mario Alberto Battaglia, Marco Salvetti, Diego Franciotta, Antonio Uccelli, Alessandro Maglione, Alessio Signori, Aniello Iovino, Carolina Gabri Nicoletti, Chiara Rosa Mancinelli, Daiana Bezzini, Daniele Carmagnini, Davide Brogi, Eduardo Nobile Orazio, Enri Nako, Ester Assandrir, Federica Baldi, Filippo Ansaldi, Francesca Bovis, Gabriele Siciliano, Gaia Cola, Giacomo Lus, Giancarlo Icardi, Gianmarco Bellucci, Giorgio Da Rin, Girolama Alessandra Marfia, Giulia Vazzoler, Giuseppe Trivelli, Ilaria Maietta, Laura Sticchi, Lorena Lorefice, Lucia Ruggiero, Marcello Manzino, Margherita Monti Bragadin, Maria Chiara Buscarinu, Maria Gagliardi, Maria Teresa Rilla, Marta Ponzano, Marzia Fronza, Massimo Del Sette, Matteo Scialabba, Michele Bedognetti, Nicola De Rossi, Nicola De Stefano, Rachele Bigi, Raffaele Dubbioso, Roberta Reniè, Sabrina Fabbri, Sarah Rasia, Simona Rolla, Stefan Platzgummer, Valentina Carlini, Sormani, Maria Pia, Schiavetti, Irene, Inglese, Matilde, Carmisciano, Luca, Laroni, Alice, Lapucci, Caterina, Visconti, Valeria, Serrati, Carlo, Gandoglia, Ilaria, Tassinari, Tiziana, Perego, Germana, Brichetto, Giampaolo, Gazzola, Paola, Mannironi, Antonio, Stromillo, Maria Laura, Cordioli, Cinzia, Landi, Doriana, Clerico, Marinella, Signoriello, Elisabetta, Cocco, Eleonora, Frau, Jessica, Ferrò, Maria Teresa, Di Sapio, Alessia, Pasquali, Livia, Ulivelli, Monica, Marinelli, Fabiana, Pizzorno, Matteo, Callari, Graziella, Iodice, Rosa, Liberatore, Giuseppe, Caleri, Francesca, Repice, Anna Maria, Cordera, Susanna, Battaglia, Mario Alberto, Salvetti, Marco, Franciotta, Diego, and Uccelli, Antonio

Subjects
Vaccines, Synthetic, Vaccines, COVID-19 Vaccines, Multiple Sclerosis, SARS-CoV-2, Messenger, Vaccination, Synthetic, Breakthrough infections, COVID-19, Disease Modifying Treatments, Cohort Studies, Humans, Prospective Studies, RNA, Messenger, mRNA Vaccines, Viral Vaccines, General Medicine, Settore MED/26, General Biochemistry, Genetics and Molecular Biology, Breakthrough infection, RNA, Disease Modifying Treatment
Abstract

Background: In this study we aimed to monitor the risk of breakthrough SARS-CoV-2 infection in patients with MS (pwMS) under different DMTs and to identify correlates of reduced protection. Methods: This is a prospective Italian multicenter cohort study, long-term clinical follow-up of the CovaXiMS (Covid-19 vaccine in Multiple Sclerosis) study. 1855 pwMS scheduled for SARS-CoV-2 mRNA vaccination were enrolled and followed up to a mean time of 10 months. The cumulative incidence of breakthrough Covid-19 cases in pwMS was calculated before and after December 2021, to separate the Delta from the Omicron waves and to account for the advent of the third vaccine dose. Findings: 1705 pwMS received 2 m-RNA vaccine doses, 21/28 days apart. Of them, 1508 (88.5%) had blood assessment 4 weeks after the second vaccine dose and 1154/1266 (92%) received the third dose after a mean interval of 210 days (range 90-342 days) after the second dose. During follow-up, 131 breakthrough Covid-19 infections (33 during the Delta and 98 during the Omicron wave) were observed. The probability to be infected during the Delta wave was associated with SARS-CoV-2 antibody levels measured after 4 weeks from the second vaccine dose (HR=0.57, p&nbsp

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results